- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01114789
Impact on the Proteolysis of Obesity in Dialysis (IPOD)
Study Overview
Detailed Description
In hemodialysis patients, the risk of death decreases almost linearly as BMI increases, including in obese patients. Experimental data suggest that obesity may be associated with a reduction of muscle proteolysis during fasting.
In the hemodialysis patients, after an overnight fast an increased use of endogenous energy stores has been reported. The objective of the study is to evaluate the potentially "protective" effect of obesity on protein catabolism during short fasting periods.
Twenty non diabetic patients (men and women) on maintenance hemodialysis for more than six months, aged of 30 to 70 years, will be included: 10 obese (BMI ≥ 30) and 10 non obese patients (18.5 <BMI <25) will be compared with 20 healthy volunteers (men and women) aged 30 to 70 years, obese and non obese, according to the same criteria.
On the investigation day, tracer kinetic studies will be associated with resting energy expenditure measurements and body composition analysis (using dual energy x-ray absorptiometry (DXA).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Clermont-Ferrand, France, 63003
- Recruiting
- CHU clermont-ferrand
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Common Criteria for patients and healthy volunteers:
- Males and females.
- Age between 30 to 70 years.
- Body Mass Index:
Selection criteria for the obese: BMI> 30 kg/m2, Selection criteria for non-obese subjects: 18.5 <BMI <25 kg/m2.
- Biological Review considered satisfactory by the investigator based on the topics covered: chronic renal (obese or not) or healthy volunteers.
- Serology HIV and HCV negative.
- Subject giving his written informed consent
- Affiliated to National Health Insurance
Specific criteria for kidney chronic patients in hemodialysis:
- Patients on hemodialysis since more than 6 months.
- Patients with a clinical stable condition defined by the absence of progressive disease.
Specific criteria for healthy volunteers:
- Subject considered as healthy after clinical examination and medical questionnaire
- Topic willing to be included in the national register of healthy volunteers.
Exclusion Criteria:
- Common Criteria for patients and healthy volunteers:
- Subject under 30 or over 70 years.
- Pregnant or lactating.
- For women of childbearing age: β-hCG assay positive and not have to contraceptives reliable (oral contraceptive, IUD, implant or hormone patch).
- Medical or surgical history (judged by the investigator to be incompatible with the study).
- Diabetics (type 1 or 2).
- Blood donation in the two months preceding the study.
- Special dietary needs (vegetarian, vegan, ...).
- Heavy alcohol consumption (> 2 to 3 glasses per day depending on sex) or presence of an addiction.
- Tobacco significant (> 5 cigarettes / day or equivalent in cigars or pipe tobacco).
- Intense sporting activity (> 5 hours / week).
- Being in exclusion on the National Volunteers Data file
- Subjects deprived of their liberty by judicial or administrative.
Specific criteria for kidney chronic patients in hemodialysis:
- Patients treated with peritoneal dialysis.
- Patients treated with daily hemodialysis.
- Albuminemia <35 g / l and transthyrétinémie <300 mg / l
Specific criteria for healthy volunteers:
- Refusal to be registered on the National Volunteers Data file
- Currently participating or who having got 4500€ in this year before to have participed in another clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Fasting muscle protein kinetics will be assessed by the isotope dilution technique using D5 phenylalanine. The isotopic plasma enrichment in phenylalanine will be measured after collection of arterialized and venous blood of the forearm.
Time Frame: 9h to 13h the day of the investigation
|
9h to 13h the day of the investigation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Whole-body protein metabolism will be assessed after 13C-leucine infusion in order to determine proteolysis, protein synthesis and protein balance,
Time Frame: 9h to 13h the day of the investigation
|
9h to 13h the day of the investigation
|
|
Resting energy metabolism will be measured by indirect calorimetry.
Time Frame: 10h to 11h and 12h to 12h40 the day of the investigation
|
10h to 11h and 12h to 12h40 the day of the investigation
|
|
Lipid metabolism will be investigated by measuring the participation of energy substrates to the energy expenditure, determination of plasma free fatty acids and calculation of VLDL synthesis rates (measuring the isotopic enrichment of apo B100).
Time Frame: the day of the investigation
|
the day of the investigation
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Yves BOIRIE, PUPH, CHU Clermont-Ferrand (CRNH)
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHU-0071
- 2008-A00729-46 (REGISTRY: IDRCB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemodialysis Patients
-
Mansoura UniversityNot yet recruitingHemodialysis Patients
-
Ataturk UniversityCompletedHemodialysis PatientsTurkey (Türkiye)
-
PulseNmoreCompletedHemodialysis PatientsIsrael
-
Taipei Medical UniversityUnknown
-
Nantes University HospitalCompleted
-
Institut Phoceen de NephrologieRecruiting
-
Ain Shams UniversityCompleted
-
Dong-A ST Co., Ltd.CompletedThe Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis PatientsHemodialysis PatientsKorea, Republic of
-
Hospital de Clinicas de Porto AlegreUnknown
-
Ataturk UniversityActive, not recruitingHemodialysis PatientsTurkey (Türkiye)
Clinical Trials on Proteolysis
-
Children's Oncology GroupRecruitingRefractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Refractory Childhood Malignant Solid Neoplasm | Recurrent Childhood Malignant Solid Neoplasm | Childhood Fibrolamellar Carcinoma | Recurrent Childhood Fibrolamellar Carcinoma | Recurrent Fibrolamellar Carcinoma | Refractory... and other conditionsUnited States
-
Healeon Medical IncTerry, Glenn C., M.D.; Ministry of Health, Honduras; Robert W. Alexander, MDWithdrawn